Eurazeo, an investment company, and Bpifrance, a French investment firm, led a €30m Series A funding round in Aqemia, a developer of a drug discovery platform, with participation from Elaia. “After repeated successes in generating very efficiently innovative new chemical matter in collaboration with large pharmaceutical companies around the world, we are now excited to leverage this fundraising to accelerate towards Aqemia’s mission: build a massive pipeline of wholly-owned drug discovery projects," Maximilien Levesque, Aqemia Co-Founder and CEO.